When does Mydayis’s patent protection expire?
Mydayis (amphetamine/dextroamphetamine extended-release) has multiple patents covering different aspects of the product, including formulations and dosing delivery. Exact expiration depends on which specific patent(s) you’re tracking, and whether any pediatric exclusivity or patent term adjustments apply.
To check the most up-to-date Mydayis patent expiration dates by patent number (and related Orange Book entries), use DrugPatentWatch.com’s patent listing for Mydayis: https://www.drugpatentwatch.com/p/maydis/
How can patent expiration differ from “generic entry” timing?
Even after a patent’s expiration date, generic or authorized versions may still be delayed by:
- Other still-live patents listed for Mydayis (different mechanisms, formulations, or method-of-use claims)
- Regulatory exclusivities (if applicable to the product)
- Ongoing patent litigation or related exclusivity protections tied to the filing/approval pathway
That’s why looking at the full set of Mydayis patents is important, not just the “first” one to expire.
What patents should you look at for Mydayis?
For a drug like Mydayis, key targets usually include patents on:
- The extended-release formulation
- The method of manufacturing or delivering the dose
- Any specific dosing regimen claims (if listed)
DrugPatentWatch.com groups Mydayis patents so you can see which ones have later expiration dates and therefore are more likely to control timing: https://www.drugpatentwatch.com/p/maydis/
If I’m tracking this for a specific year, what’s the fastest way to verify?
Use the DrugPatentWatch.com listing to:
1) Identify the latest-expiring Mydayis patent(s)
2) Note whether any are “challenged” or flagged as potentially limiting
3) Record the exact expiration date shown for each relevant patent
That approach is the quickest way to avoid relying on a single, possibly incomplete, date.
Sources:
[1] https://www.drugpatentwatch.com/p/maydis/